Industry perspective on Generative Al in HEOR

Vladimir Babiy

PhD, PharmD
Associate Director, HEOR
Novartis



Disclaimer

I am a Novartis associate. The statements, views, and opinions expressed in this presentation are solely my own and do not represent the official policies, positions, or opinions of my employer or any of its affiliates. This presentation is provided in a personal capacity and is not intended to reflect or convey any official endorsement or stance by my employer.

Plan

- Present & Future of AI in HEOR
- Feasibility of using AI for health economic modeling
- Implications
- Challenges or barriers faced by pharma in the adoption of Al



Where will the bottleneck be?

10% increase in success rates of trials20% reduction in cost and duration of trialsTime to approval accelerated by 1-2 years

Is there enough bandwidth in HEOR?



Present & Future of Al in HEOR

Evolution? Disruption? → Transformation.

Experiments with Machine Learning (Analytic AI)

Key question:

Is it possible to analyze huge amounts of data? (with RWE in mind)

Tusks:

- Screening
- Data extraction

Learnings:

- It works.
- Data formats differ
- "Teaching" is resource consuming

Experiments with Generative AI, Deployment of Analytic AI

Key question:

Is it possible to change how data turns into evidence?

Tusks:

- Evidence generation
- Modeling
- Translation between languages:
 - natural language ↔
 programming language ↔
 HEOR language

Learnings:

• It works but lacks consistency...

Future is uncertain, but transformative

Key questions:

- How should processes be altered to better leverage the technology?
- Transformation of HEOR roles:
 - Project Managers → AI Managers?
- Will GenAI lead to the democratization of HEOR?
 - Generative AI can become a great equalizer to HEOR evidence generation and consumption



Feasibility of using Generative AI for health economic modeling

Breakthroughs in Generative Multimodal Al

- No training, just tune your Al
- - Excel, R, Python
- Al understands information from multiple modalities: text, numbers, images, audio, and video
- Al is now being integrated into standard environments, incl. Excel, Word
- NEW! Model capable of searching web in real-time




Efficiency is improved, but resource utilization is balanced

Al will rather be a cost-effective approach to generating evidence, than dominant

↑ Corpus of evidence ↑ Number of PICOs

↓ Tolerance to uncertainty ↑ Transparency and referencing ↑ Complexity of human validation






Will anyone notice exponential growth of HEOR performance?

Probably **yes**, and definitely **not** by everyone.

Industry will just meet again the increased expectations



"My dear, here we must run as fast as we can, just to stay in place.

And if you wish to go anywhere you must run twice as fast as that."²



History lessons

How have vacuum cleaners changed our lives?

- Free up time?
- Vacuum cleaners have changed our expectations of what "clean" means
 - In early XX no one expected your carpet to be pristine all winter when it only got pulled up and beaten in the spring. Now, some people want to see the vacuum lines all the time.



Challenges faced by pharma in adoption of Al

People

- Insufficient AI literacy
- Lack of available talent and skills
 - Unlearning skills

Processes

- Lack of a clear AI case for change
- Reimagining workflows and implementing processes on the go
- AI can become lazy (like human). How to manage?

Grey zone at the Methodological acceptance landscape

• Bias


Medicine = Substance + Information

Al in Industry HEOR =

= Technology + Processes + User



Al Chatbots are **biased** in the **same** way







01-Jan-2024

Once AI is deployed in HEOR...

Will there be trust in evidence generated without AI?



Thank you for your attention



